STOCK TITAN

HUTCHMED (China) Limited - HCM STOCK NEWS

Welcome to our dedicated news page for HUTCHMED (China) (Ticker: HCM), a resource for investors and traders seeking the latest updates and insights on HUTCHMED (China).

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect HUTCHMED (China)'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of HUTCHMED (China)'s position in the market.

Rhea-AI Summary
HUTCHMED (China) Limited (HCM; 13) Reports 164% Revenue Growth, Net Income of US$169 million, and Strategic Progress in Global Partnership with Takeda
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.42%
Tags
none
-
Rhea-AI Summary
HUTCHMED (China) Limited has received Breakthrough Therapy Designation from China's NMPA for the combination of fruquintinib and sintilimab in the treatment of advanced endometrial cancer. The study for potential registration of this combination has completed enrollment with 142 previously treated patients. Positive results from the trial could lead to regulatory approval in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.07%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
management
Rhea-AI Summary
HUTCHMED has initiated a Phase I study in China of HMPL-415, an investigational inhibitor targeting SHP2. The study aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HMPL-415 in patients with advanced malignant solid tumors. The study is expected to enroll up to approximately 80 patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.89%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.43%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.38%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.38%
Tags
-
-
Rhea-AI Summary
HUTCHMED announces new clinical data on two investigational hematological malignancy therapies to be presented at upcoming conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
HUTCHMED announces new clinical data on cancer therapies to be presented at ASCO Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.66%
Tags
none
HUTCHMED (China) Limited

Nasdaq:HCM

HCM Rankings

HCM Stock Data

3.14B
1.00B
0.13%
9.43%
0.29%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
HK
Central

About HCM

HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs.